Genome Editing Market Size is Anticipated to Reach USD 13.36 billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, genome editing technologies have emerged as one of the fastest growing segments in the biopharmaceutical industry, owing to their superior precision, efficiency, and versatility in modifying genetic material, along with seamless integration with advanced delivery systems leading to a significant growth in the overall genome editing market.

Global Genome Editing Market Overview

The global genome editing market is expected to reach around USD 13.36 billion by 2035, growing at a CAGR of 10.8% during the forecast period till 2035.

Over time, the pharma / biotech sector has adopted genome editing technologies across various processes, including drug discovery, drug development, and manufacturing. In drug discovery, genome editing platforms such as CRISPR-Cas systems provide unparalleled precision for high-throughput functional genomics screens, target identification and validation, thereby accelerating the identification of novel drug candidates. During drug development, genome editing enables the generation of advanced cell and gene therapies, precise correction of genetic defects, and optimization of clinical trial designs through better disease modeling and patient stratification. Moreover, the implementation of genome editing tools are deemed to possess the potential to significantly reduce the time and cost of drug development programs by streamlining target validation and preclinical testing phases. In addition, in manufacturing, genome editing enhances the production of biologics and cell therapies by engineering stable, high-yield producer cell lines and improving product consistency. With improved delivery systems, enhanced safety profiles through next-generation editors (such as base and prime editing), and streamlined regulatory pathways for platform technologies, the genome editing market is poised for sustained growth.

Browse 110+ figures and 150+ market data tables spread across 300+ pages and detailed Table of Content on “Genome Editing Market, till 2035 by Type of Payment Method Employed (Upfront Payments and Milestone Payments), Distribution by Type of Gene Editing Technique (CRISPR-Cas System, TALENs, Meganucleases, ZFNs and Other Techniques), Type of Therapy (Cell Therapies, Gene Therapies and Other Therapies), Gene Editing Approach (Gene Knock-Out and Gene Knock-In), Type of Gene Delivery Method (Ex vivo and In vivo), Gene Delivery Modality (Viral Vectors and Non-Viral Vectors), Application Area (Drug Discovery and Development, and Diagnostics), Type of End-User (Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes), Key Geographical Regions (North America, Europe and Asia-Pacific), and Leading Industry Players” here https://www.rootsanalysis.com/reports/genome-editing-market.html

Market Drivers

Market growth is fueled by various factors, including the increasing prevalence of genetic disorders and chronic diseases, which has significantly heightened the demand for long-term and curative treatment options. Further, the expanding applications of genome editing tools such as CRISPR-Cas9 are accelerating market momentum by enabling highly targeted genetic modifications with minimized off-target effects across gene and cell therapy development. Additionally, rapid technological advancements including base editing, prime editing, and transposon-based systems, are addressing the limitations of conventional methods and driving greater precision, efficiency, and innovation. This has led to sustained growth and broader adoption of genome editing technologies across therapeutic and research applications.

Market Restraints

While the global genome editing market is experiencing substantial growth, there are certain restraints that can hinder the growth of the industry. One of the primary challenges is the high cost of genome-edited drugs and therapies. This can be attributed to the fact that the development of these precise genetic interventions requires extensive research, specialized delivery systems and complex manufacturing processes, thereby, significantly elevating expenses for developers. Additionally, stringent regulatory governance, complex intellectual property disputes surrounding key technologies like CRISPR-Cas9, and persistent safety and ethical concerns, including off-target effects and potential carcinogenicity, continue to hinder broader market adoption. These factors, combined with extended clinical timelines and increased compliance burdens, collectively act as barriers to wider adoption, challenging the market’s ability to sustain its growth trajectory.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global genome editing market forward. One notable factor is the increasing partnership activity, indicating rising interest of established players in this domain. The stakeholders have been actively collaborating with other players for various purposes, such as technology licensing, research and development, product licensing agreements, product development and commercialization. Moreover, over the years, there has been a significant increase in the number of investments made by various stakeholders in the companies working in the genome editing domain. The trend indicates an opportunity for growth for the players involved in this market.

Global Genome Editing Market Segments

Based on the type of payment method employed, the market is segmented into upfront payments and milestone payments.

• Milestone payment sub-segment led the global genome editing market, capturing the largest revenue share of 54% in the current year and is likely to grow at a higher CAGR (15.4%) during the forecast period.
• This trend is likely to change in the forecast period, with milestone payments generating 62% of the revenue in the coming decade.

Based on the type of gene editing technique, the market is segmented into CRISPR-Cas system, TALENs, meganucleases, ZFNs and other techniques.

• In the current year, the CRISPR-Cas System sub-segment led the global genome editing market, capturing the largest revenue share of 84% and is likely to grow at a higher CAGR (11.1%) during the forecast period.
• This can be attributed to the fact that next-generation CRISPR technologies (base and prime editing) have demonstrated promise in overcoming the limitations associated with conventional gene editing techniques, by offering more customized and precise results.

Based on the type of gene editing approach, the market is segmented into gene knock-out and gene knock-in.

• In the current year, the gene knock-out sub-segment led the global genome editing market, capturing the largest revenue share of 53% and is likely to grow at a higher CAGR (11.7%) during the forecast period.
• This can be attributed to the greater feasibility and accessibility of this approach, over the knock-in approach, since knock-in approaches require a complex optimization process.

Based on the type of gene delivery method, the market is segmented into ex vivo and in vivo.

• In the current year, the ex-vivo sub-segment led the global genome editing market, capturing the largest revenue share of 62%.
• It is worth highlighting that the market share for in vivo is likely to grow at a relatively higher CAGR (12.0%), during the forecast period.

Based on the type of gene delivery modality, the market is segmented into viral vectors and non-viral vectors.

• Viral vectors sub-segment led the global genome editing market, capturing the largest revenue share of 55% in the current year.
• It is worth highlighting that the market share for non-viral vectors is likely to grow at a relatively higher CAGR (12.0%), during the forecast period.

Based on the type of therapy, the market is segmented into cell therapy, gene therapy and others.

• In the current year, the cell therapy sub-segment led the global genome editing market, capturing the largest revenue share of 65%.
• It is worth highlighting that the market share for gene therapy is likely to grow at a relatively higher CAGR (11.6%), during the forecast period.

Based on the application area, the market is segmented into drug discovery and development, and diagnostics.

• Drug discovery and development companies sub-segment led the global genome editing market, capturing the largest revenue share of 82% in the current year.
• It is worth highlighting that the market share for diagnostics is likely to grow at a relatively higher CAGR (13.0%), during the forecast period.

Based on the end-user, the market is segmented into pharmaceutical and biotechnology companies, and academic and research institutes.

• Pharmaceutical and biotechnology companies sub-segment led the global genome editing market, capturing the largest revenue share of 82% in the current year.
• It is worth highlighting that the market share for academic and research institutes is likely to grow at a relatively higher CAGR (11.9%), during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America.

• North America is dominating the global genome editing market, accounting for the largest revenue share of 73% in the current year.
• It is worth highlighting that the market share for Europe is likely to grow at a relatively higher CAGR (12.7%), during the forecast period.

Key Companies Profiled

The global genome editing market report also includes detailed profiles of key players (listed below):

• Arcturus Therapeutics
• ArsenalBio
• Avectas
• Beam Therapeutics
• Bio-Sourcing
• Caribou Biosciences
• Century Therapeutics
• CRISPR Therapeutics
• Editas Medicine
• Flash Biosolutions
• Graphite Bio
• Intellia Therapeutics
• NTrans Technologies
• OXGENE
• Prime Medicine
• Revvity
• Vor Biopharma

You Can Download Free Sample PDF Copy of This Report At:

https://www.rootsanalysis.com/reports/genome-editing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 1,500 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com